The principle behind our Medtech
Unsuspected utility of known drugs
CXS Therapeutics' own working methodology for optimized identification of the molecule of interest.
Bioinformatics identification tools
Accelerated through a transdisciplinary process using targeted exploration of several scientific databases.
Meeting therapeutic needs
In diseases affecting the central nervous system, through selection of clinically relevant therapeutic targets.
Focus on central nervous system
A pragmatic choice
High prevalence
900,000 people suffer from Alzheimer's, 150,000 from multiple sclerosis, and around 270,000 from Parkinson.
Considerable burden
Quality of life, socio-economic costs. Ageing population and rising incidence in the under-50s.
Need for innovation
Improved diagnosis, treatment, healthcare policies and support for patients and their families.
Medical needs
Only drugs aimed at slowing disease progession and controlling the symptoms.
A choice motivated by the personal history of one of the founders
Parkinson sur Loire" challenge
Raising funds to run a first set of experiments for a disease-modifying treatment.
Creation of CXS Therapeutics
Provisional patent for treatment and application of research methodology to CNS diseases.
The message from Guillaume
The discovery of his pathology, the genesis of our medtech platform, his feelings as the adventure unfolded - he tells you all about it!
The advantages of repurposing
Treating a disease with a drug from another therapeutic area. Offering new therapeutic indications to patients by addressing 4 main issues.
Security
Already approved and proven drugs. Benefit from existing clinical safety data.
Emergency
Make effective treatments available as quickly as possible for patients awaiting.
Economy
Reducing both the costs and time needed to bring a new therapy to market.
Search
Discovering new potential for drugs used in unrelated therapeutic areas.
Application to neurological disorders
A major challenge in terms of developing effective new treatments for Alzheimer's, Parkinson's, multiple sclerosis and other central nervous system disorders.
Chronic, incurable and disabling diseases
Large number of patients affected
Multifactorial diseases involving complex mechanisms
Lack of effective therapies
Innovative tools
developed by CXS
An investigation methodology designed for optimal pharmaceutical redevelopment.
Methodology
Choice of pathology of interest in the neurological field
Identification of compensating factor(s)
Pharmaceutical redevelopment of identified candidates
Specifications
Correlation with expression level and identification of mechanism
Origin of major risk factor(s) and identification of a market
Molecule free of rights or unused rights
Means of implementation
Bibliography without a priori and targeted related pathologies
Databases, experimental protocols.
Form, (co)formulation, administration : PI
Our first hit, the Parkinson's disease
Essential reminder
● Parkinson's disease is the 2nd most common neurodegenerative after Alzheimer's disease.
● It affects 270,000 people in FranceThis figure is rising steadily as the population ages.
● It is characterized by degeneration of the dopaminergic neurons.
● From a symptomatic standpoint, known clinical signs include tremorstremors slowness of movement and muscular rigidity.
The aim of our treatment?
The aim of current treatments is to compensate for the dopamine deficiency. In short, they aim to correct the symptoms but not to stop the mechanism at the origin of the disease. Keeping that in mind, our work aims at restoring dopaminergic production by achieving efficient neuroprotection.
Find out more about the Parkinson's hit on SAPPIENS
SAPPIENS is a subsidiary created following the identification of this first drug candidate by CXS Therapeutics. Its objective is to carry out the pharmaceutical development of a first neuroprotective treatment, the CXS003.
Actors
behind CXS Therapeutics
Above all, a group. A complementary group, welded together and motivated by Guillaume's fight, as well as by a common desire: to offer treatments for CNS diseases where the need exists.
Guillaume Brachet
Hospital pharmacist, researcher and expert in biopharmaceuticals, vaccinology and pharmacology, consultant in pharmaceutical innovation.
Anthony Alioui
PhD in genetics and molecular physiology, founder of MS PEDAGO (health promotion organization) and expert in educational engineering and communication.
Nadine Mackenzie
Rheumatologist, medical director in the pharmaceutical industry for 20 years, and former member of the Management Committee of LEO Pharma France.
Philippe Nussbaumer
Expert in the creation and development of innovative companies, co-founder of the biotech company ALAXIA, co-founder of an early stage Deeptech investment fund.
Djamchid Dalili
Polytechnic and PhD in nuclear physics, founder of the 3W Academy (developer school), founder and CEO of medtech DIAMPARK (Parkinson disease).
Gabrielle Gache
Master's degree in economics and MBA (HEC). Market access and pharmaceutical Business Dev. for 30 years. Member of the Board of Directors of the Swiss licensing group from 2015 to 2022.
They are already taking part in the adventure
Want to invest? Write to us.
Assuming you already grasped this from our approach, but therapeutic efficacy is the guarantee of our profitability.
